Beyond Exon 2 — The Developing Story of RAS Mutations in Colorectal Cancer
Mené sur 639 patients atteints d'un cancer colorectal métastatique ne présentant pas de mutations dans l'exon 2 du gène KRAS, cet essai évalue l'ajout de patinumumab à une chimiothérapie FOLFOX4 en fonction de la présence de mutations dans d'autres exons du gène KRAS
Initial single-agent studies of anti–epidermal growth factor receptor (anti-EGFR) antibodies in the treatment of colorectal cancer showed that these agents were marginally effective. The minority of patients derived benefit, as evidenced by progression-free survival curves that had no inflection until well after the 50% mark. However, after the determination that activating mutations in exon 2 of the gene KRAS predicted the inefficacy of anti-EGFR antibodies, reanalyses of multiple trials suggested that these agents could be more effective when administered to a more limited cohort of patients. Thus, mutations in exon 2 of KRAS became the first biomarkers of colorectal . . .